Equities research analysts expect Xencor Inc (NASDAQ:XNCR) to report $7.58 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Xencor’s earnings. The highest sales estimate is $15.10 million and the lowest is $3.50 million. The company is expected to report its next quarterly earnings results on Monday, August 5th.
On average, analysts expect that Xencor will report full-year sales of $127.78 million for the current year, with estimates ranging from $123.00 million to $135.46 million. For the next financial year, analysts anticipate that the company will post sales of $40.46 million, with estimates ranging from $8.00 million to $90.57 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Xencor.
Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.43 by $0.95. The firm had revenue of $111.94 million during the quarter, compared to analysts’ expectations of $60.05 million.
XNCR has been the subject of a number of recent research reports. Berenberg Bank reduced their price objective on Lucara Diamond from C$1.60 to C$1.50 in a research note on Wednesday, March 27th. Piper Jaffray Companies set a $92.00 target price on Wintrust Financial and gave the company a “buy” rating in a research report on Monday, July 8th. Mizuho set a $21.00 target price on Neon Therapeutics and gave the company a “buy” rating in a research report on Monday, July 1st. ValuEngine cut Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Finally, Zacks Investment Research cut Zynex from a “hold” rating to a “sell” rating in a research report on Saturday, May 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. Xencor has an average rating of “Buy” and an average target price of $43.44.
Shares of NASDAQ XNCR traded up $0.41 during trading on Friday, reaching $44.34. 415,811 shares of the company traded hands, compared to its average volume of 1,074,439. The company has a fifty day moving average price of $36.03. The firm has a market cap of $2.48 billion, a PE ratio of -33.85 and a beta of 1.45. Xencor has a 12-month low of $27.75 and a 12-month high of $48.38. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.66 and a current ratio of 6.66.
In other Xencor news, major shareholder John S. Stafford III bought 14,611 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were acquired at an average cost of $29.87 per share, with a total value of $436,430.57. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder John S. Stafford III bought 12,641 shares of the firm’s stock in a transaction on Thursday, June 6th. The stock was acquired at an average cost of $29.87 per share, for a total transaction of $377,586.67. The disclosure for this purchase can be found here. Company insiders own 4.33% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in XNCR. FMR LLC grew its stake in shares of Xencor by 0.7% in the fourth quarter. FMR LLC now owns 8,435,149 shares of the biopharmaceutical company’s stock worth $305,015,000 after acquiring an additional 61,233 shares in the last quarter. BlackRock Inc. grew its stake in shares of Xencor by 2.5% during the fourth quarter. BlackRock Inc. now owns 4,152,607 shares of the biopharmaceutical company’s stock worth $150,159,000 after purchasing an additional 100,924 shares in the last quarter. Norges Bank acquired a new position in shares of Xencor during the fourth quarter worth $28,271,000. Northern Trust Corp grew its stake in shares of Xencor by 0.3% during the fourth quarter. Northern Trust Corp now owns 603,917 shares of the biopharmaceutical company’s stock worth $21,838,000 after purchasing an additional 1,751 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Xencor by 7.4% during the fourth quarter. Geode Capital Management LLC now owns 550,642 shares of the biopharmaceutical company’s stock worth $19,911,000 after purchasing an additional 38,127 shares in the last quarter. 83.51% of the stock is currently owned by hedge funds and other institutional investors.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Featured Article: What is insider trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.